To access this material please log in or register

Register Authorize

Evidence-based history of candesartan: past, future and present

Gilyarevsky S. R.1, Golshmid M. V.1, Kuzmina I. M.2
1 – State Budgetary Educational Institution of Advanced Professional Education, “Russian Medical Academy of Postgraduate Education” of the RF Ministry of Health Care, Barrikadnaya 2/1, Moscow 123995
2 – N. V. Sklifosovsky Research Institute of Emergency Medicine, B. Sukharevskaya Pl. 3, Moscow 129090

Keywords: candesartan, treatment, cardiovascular diseases

DOI: 10.18087/rhfj.2015.5.2155

The review analyzes the role of candesartan in prevention of CVD complications.
  1. JBS3 Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014;100 Suppl 2: II1‑II67.
  2. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006 Apr 20;354 (16):1685–97.
  3. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hyperens. 2003 May;21 (5):875–86.
  4. Schunkert H. Pharmacotherapy for prehypertension – mission accomplished? N Engl J Med. 2006 Apr 20;354 (16):1742–4.
  5. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008 Aug;7 (8):683–9.
  6. Birns J, Morris R, Donaldson N, Kalra L. The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J Hypertens. 2006 Oct;24 (10):1907–14.
  7. Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-Levi AC, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013 Jun;31 (6):1073–82.
  8. Kjeldsen SE, Stålhammar J, Hasvold P, Bodegard J, Olsson U, Russell D. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens. 2010 Apr;24 (4):263–73.
  9. McMurray J, Ostergren J, Pfeffer M, Swedberg K, Granger C, Yusuf S et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2003 Jun;5 (3):261–70.
  10. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G et al. Candesartan in heart failure – assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail. 1999 Sep;5 (3):276–82.
  11. Gelow J. M., Fang J. C. Update in the approach to and management of heart failure. South Med J 2006;99:1346–1355.
  12. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ et al. Effect of losartan compared with captopril on morta­lity in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000 May 6;355 (9215):1582–7.
  13. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 Dec 6;345 (23):1667–75.
Gilyarevsky S. R ., Golshmid M. V., Kuzmina I. M. Evidence-based history of candesartan: past, future and present. Russian Heart Failure Journal. 2015;16 (5):303–310

To access this material please log in or register

Register Authorize
Ru En